FOLINATE DE CALCIUM HIKMA 10 mg/mL

DRUG3 trials

Sponsors

Fondation Franc.Cancerologie Digestive, Institut De Recherches Internationales Servier IRIS

Conditions

BRAF and Other Selected RAS/MAPK MutationsMalignancies with Documented KRASResectable borderline pancreatic adenocarcinomacolorectal cancer

Phase 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Not yet recruitingCTIS2025-523474-16-00

Institut De Recherches Internationales Servier IRISBRAF and Other Selected RAS/MAPK Mutations, Malignancies with Documented KRAS

Target: 75Updated: 2026-04-22

Phase 2

ENGIC - 01 COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma

RecruitingCTIS2024-514030-20-00

Fondation Franc.Cancerologie Digestivecolorectal cancer

Start: 2025-08-29Target: 37Updated: 2026-01-13

PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.

Not yet recruitingCTIS2024-519753-11-00

Fondation Franc.Cancerologie DigestiveResectable borderline pancreatic adenocarcinoma

Target: 110Updated: 2025-10-17